default author photo

Howard I. Scher

Memorial Sloan Kettering Cancer Center

New York, NY 10065

United States

SCHOLARLY PAPERS

2

DOWNLOADS

151

TOTAL CITATIONS

1

Scholarly Papers (2)

1.

Accelerating Drug Development in Hormone-Naïve Prostate Cancer and Changing the Paradigm from Palliation to Cure: The Metacure Phase 2 Randomized Clinical Trial

Number of pages: 29 Posted: 23 Aug 2024
Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Harvard University - Dana-Farber Cancer Institute, University of Chicago, Pritzker School of Medicine, University of Chicago Hospitals, Harvard University - Dana-Farber Cancer Institute, Harvard University, Cleveland Clinic, Cleveland Clinic, Harvard University - Dana-Farber Cancer Institute, Harvard University - Brigham and Women's Hospital, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, University of Chicago, Pritzker School of Medicine, University of Chicago Hospitals, Harvard University, Indiana University Purdue University Indianapolis (IUPUI) - Indiana University School of Medicine, Cleveland Clinic, Northwestern University - Robert H. Lurie Comprehensive Cancer Center, Northwestern University - Robert H. Lurie Comprehensive Cancer Center, Northwestern University - Robert H. Lurie Comprehensive Cancer Center, University of Chicago, Pritzker School of Medicine, University of Chicago Hospitals, Memorial Sloan Kettering Cancer Center, Harvard University - Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center
Downloads 116 (613,149)

Abstract:

Loading...

Androgen deprivation therapy, Metastatic prostate cancer, Radical prostatectomy, Stereotactic body radiotherapy

2.

Optimal Systemic Treatment and Real-World Clinical Application of Ctdna in Patients with Metastatic Her2-Mutant Lung Cancer

Number of pages: 15 Posted: 15 May 2024
Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Exact Sciences Corporation, Memorial Sloan Kettering Cancer Center - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center and Memorial Sloan Kettering Cancer Center
Downloads 35 (1,249,711)
Citation 1

Abstract:

Loading...

immunotherapy, Targeted Therapy, HER2 mutation, ctDNA, NSCLC